Prosight Management’s Sio Gene Therapies SIOX Stock Holding History
Bought
Maintained
Sold
Other funds holding SIOX
NM
Prosight Management's SIOX Position: Q2 2022 in Review
Prosight Management sold out of Sio Gene Therapies (SIOX) in Q2 2022, closing a stake of 670,300 shares — an estimated $449K sold.
Prosight Management first reported a position in SIOX in Q1 2021 and held it in 5 quarters. The position peaked at $1.07M in Q3 2021. 41 funds tracked by Wall St. Rank hold SIOX as of Q2 2022.
- Prosight Management reported no remaining Sio Gene Therapies position as of Q2 2022 after selling out during the quarter.
- Prosight Management sold 670,300 Sio Gene Therapies shares in Q2 2022, an estimated $449K.
- Prosight Management first reported a position in Sio Gene Therapies in Q1 2021 and held it in 5 quarters.
- Prosight Management's Sio Gene Therapies position peaked at $1.07M in Q3 2021.
- 41 funds tracked by Wall St. Rank held Sio Gene Therapies as of Q2 2022.
Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.